The U.S. Food and Drug Administration (FDA) has issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of popular weight-loss and diabetes drugs.

Compounded Drugs Not FDA-Approved

These versions are customized medicines made when a licensed pharmacist or physician combines, mixes, or alters drug ingredients to meet the needs of an individual patient. They are not approved by the FDA. The health regulator previously sent a series of warning letters to telehealth firms as part of its broader crackdown on compounded drugs.

Some telehealth companies claimed on their websites that their compounded versions of Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide were sourced from FDA-approved pharmacies or were clinically studied, the regulator said in the letters. For others, the agency noted the representations made by the telehealth firms regarding compounded semaglutide and tirzepatide products are false or misleading.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.